about
Stabilization of high-risk plaquesIs the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?The metabolic vascular syndrome - guide to an individualized treatmentTherapeutic Use of Metformin in Prediabetes and Diabetes PreventionPPAR-γ -- a possible drug target for complicated pregnanciesDetection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012Role of Peroxisome Proliferator-Activated Receptor γ in Ocular DiseasesGenetic and epigenetic control of metabolic healthSmooth Muscle-Targeted Overexpression of Peroxisome Proliferator Activated Receptor-γ Disrupts Vascular Wall Structure and FunctionManagement of pancreatogenic diabetes: challenges and solutionsMetformin and metabolic diseases: a focus on hepatic aspectsEffects of resveratrol in experimental and clinical non-alcoholic fatty liver diseaseAnti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers.Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Pioglitazone use and risk of bladder cancer: population based cohort study.Revisiting PPARγ as a target for the treatment of metabolic disordersPharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health SurveyHypoglycemic Activity through a Novel Combination of Fruiting Body and Mycelia of Cordyceps militaris in High-Fat Diet-Induced Type 2 Diabetes Mellitus Mice.Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six CountriesDesign, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ AntagonistsClozapine modifies the differentiation program of human adipocytes inducing browning.Endothelial PPAR-γ provides vascular protection from IL-1β-induced oxidative stressThe effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort studyIn vitro Screening and Evaluation of 37 Traditional Chinese Medicines for Their Potential to Activate Peroxisome Proliferator-Activated Receptors-γ.Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms.Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies.Use of pioglitazone in the treatment of diabetes: effect on cardiovascular riskA role for Peroxisome Proliferator-Activated Receptor Beta in T cell developmentAdipocyte-specific loss of PPARγ attenuates cardiac hypertrophy.Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.Current clinical evidence on pioglitazone pharmacogenomics.PPARγ signaling and metabolism: the good, the bad and the future.Pharmacological approaches to restore mitochondrial function.Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study.The effect of Korean Red Ginseng extract on rosiglitazone-induced improvement of glucose regulation in diet-induced obese mice.Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation
P2860
Q26738584-1F8DE68F-48C3-4CD4-A328-76E007735394Q26739984-1C78F6D9-480C-4C4F-AE2B-28C9F4928110Q26767142-5700C7FF-9D9F-402A-9DFF-04FFEF653483Q26822066-C0D6B038-7AD7-4E72-A6EA-0F741B941723Q26863678-E47402B4-CC7E-4632-8246-D4C61327CFCDQ27007060-0AD731F2-15D5-454D-9ADF-38A5DD416845Q27022548-3DB9320B-1536-4628-8559-85395BA0DCBEQ27026287-623AF6EC-D2BE-4EB7-8E58-CB7DCA62C75CQ27315042-65AEB3EC-B644-440C-861E-66633C7A6117Q28069386-84E9A6C7-79FC-44D2-B2E8-782BCC7A903DQ28082736-2513AF4D-7405-4FF5-9FB8-51079DBD424CQ33563877-FD8E0B72-DD2F-4A82-ACCF-AC88EE89F7A2Q33600223-C263CE6D-86DF-499F-BB88-8FC179A181D2Q34563587-2593978B-9A29-4091-B454-16128304308AQ34676639-BE455662-56F5-4C51-9767-72DEE780AC25Q34798213-57B176FD-3C06-4FAD-A62F-E334D02FEB81Q35039274-3F11B21D-62BA-431A-B7A7-122E561446E3Q35189862-9D242B5E-7CFF-4FA2-A240-093920DE8FA6Q35604695-2252AB35-01E8-4776-85D5-0407B96E85D8Q35901526-B2D00462-E86A-45C6-8C1B-F1B9AA480DADQ36034337-B68B0685-CABB-4BF2-B2D1-6A78CB429DFAQ36059797-ABF318DC-E1AD-4FB7-A7BB-A9180095C509Q36206591-BE1190EF-D2B1-43F1-B16D-77DF45550C22Q36699263-EEB7884D-6A94-42E1-8389-33921EC378C6Q36710078-7BAF85ED-EDC7-4E26-9FA0-8404141D53F0Q36733126-3DCF55F3-2483-4978-B0EA-1D60DB4FEE52Q36734040-5C4EE0E3-922D-4927-B945-8AE169D199B7Q36833317-804A0E4F-8B11-4376-92D9-097E01B7BE74Q37151347-D09EE232-DAAD-437E-A2EF-B9E7EDE80DFCQ37294323-63807D76-DDC2-4321-8368-DAEC19960258Q37316215-5993929E-B0E1-450F-B1B2-E7D915B06B8DQ37342122-CB0FD1FF-F580-49F1-BF09-03F99CF6B6E4Q37342358-629758B1-4D29-4D97-B612-756BE2EAA4A1Q37407887-ED3D0A54-C61E-4573-9B80-15A00B8308AFQ37497833-9A66B6AB-D1FF-4D13-97A3-9B9A587480A9Q37521990-3F16D64E-9979-44DA-B7E8-B779EDDF84AEQ37575660-B7FC5D39-1E70-4DFE-BE0B-BA901CC8EE8BQ37577159-A9044DBA-4029-424A-B55D-33C58B01DF23Q37590946-8A72E7E1-DA77-4E45-861E-7E8B25DDC104Q37631143-CB0542E6-9C7C-4190-B66E-4DE31EFA0937
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Thiazolidinedione safety.
@en
type
label
Thiazolidinedione safety.
@en
prefLabel
Thiazolidinedione safety.
@en
P2860
P1476
Thiazolidinedione safety.
@en
P2093
Jacqueline Kung
Robert R Henry
P2860
P304
P356
10.1517/14740338.2012.691963
P407
P577
2012-05-22T00:00:00Z